NCT02225093View on ClinicalTrials.gov

A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

October 2, 2013

Primary Completion Date

February 3, 2014

Study Completion Date

February 3, 2014

Conditions

Pharmacokinetics of DextromethorphanPharmacokinetics of CaffeineProstate Cancer

Interventions

DRUG

Caffeine

Oral

DRUG

Dextromethorphan

Oral /.L

DRUG

Enzalutamide

Oral

DRUG

Enzalutamide Placebo to Match (PTM)

Oral

Trial Locations (1)

2025

Arensia, Chisinau

Sponsors

Collaborators (1)

Medivation, Inc.

All Listed Sponsors

collaborator

Medivation, Inc.

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY